Cargando…

Safety and efficacy of tolcapone in Parkinson’s disease: systematic review

PURPOSE: Tolcapone is an efficacious catechol-O-methyltransferase inhibitor for Parkinson’s disease (PD). However, safety issues hampered its use in clinical practice. We aimed to provide evidence of safety and efficacy of tolcapone by a systematic literature review to support clinicians’ choices in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Artusi, Carlo Alberto, Sarro, Lidia, Imbalzano, Gabriele, Fabbri, Margherita, Lopiano, Leonardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128808/ https://www.ncbi.nlm.nih.gov/pubmed/33415500 http://dx.doi.org/10.1007/s00228-020-03081-x

Ejemplares similares

Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson’s disease
por: Montanaro, Elisa, et al.
Publicado: (2021)

COVID-19 in Parkinson's disease: Report on prevalence and outcome
por: Artusi, Carlo Alberto, et al.
Publicado: (2020)

SARS-CoV-2 vaccination, Parkinson’s disease, and other movement disorders: case series and short literature review
por: Imbalzano, Gabriele, et al.
Publicado: (2022)

Deep Brain Stimulation Outcomes in Parkinson's Disease Patients with Cognitive Impairment: Implications and Considerations
por: Romagnolo, Alberto, et al.
Publicado: (2023)

The efficacy of homemade tolcapone in the treatment of patients with Parkinsons disease
por: Zhang, Pei-Lan, et al.
Publicado: (2018)

Utility of tolcapone in fluctuating Parkinson’s disease
por: Stocchi, Fabrizio, et al.
Publicado: (2006)

Should we offer deep brain stimulation to Parkinson’s disease patients with GBA mutations?
por: Artusi, Carlo Alberto, et al.
Publicado: (2023)

Assessment of Axial Postural Abnormalities in Parkinsonism: Automatic Picture Analysis Software
por: Artusi, Carlo Alberto, et al.
Publicado: (2023)

Time to onset and duration of botulinum toxin efficacy in movement disorders
por: Ledda, Claudia, et al.
Publicado: (2022)

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features
por: Antonini, Angelo, et al.
Publicado: (2008)

Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic
por: Montanaro, Elisa, et al.
Publicado: (2021)

Camera- and Viewpoint-Agnostic Evaluation of Axial Postural Abnormalities in People with Parkinson’s Disease through Augmented Human Pose Estimation
por: Aldegheri, Stefano, et al.
Publicado: (2023)

Deep Brain Stimulation Selection Criteria for Parkinson’s Disease: Time to Go beyond CAPSIT-PD
por: Artusi, Carlo Alberto, et al.
Publicado: (2020)

Micro- and Nano-Systems Developed for Tolcapone in Parkinson’s Disease
por: Casanova, Yaquelyn, et al.
Publicado: (2022)

Burden of caregiving for cardiovascular dysautonomia in Parkinson’s disease
por: Ledda, Claudia, et al.
Publicado: (2022)

Pisa Syndrome in Parkinson's Disease Is Associated With Specific Cognitive Alterations
por: Artusi, Carlo Alberto, et al.
Publicado: (2019)

Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson’s disease
por: Truong, Daniel D
Publicado: (2009)

How resistant are levodopa‐resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease
por: Imbalzano, Gabriele, et al.
Publicado: (2022)

COVID-19 and Parkinson’s Disease: What Do We Know So Far?
por: Artusi, Carlo Alberto, et al.
Publicado: (2021)

Effects of tolcapone and bromocriptine on cognitive stability and flexibility
por: Cameron, Ian G. M., et al.
Publicado: (2018)

Formulation of Sustained Release Hydrophilic Matrix Tablets of Tolcapone with the Application of Sedem Diagram: Influence of Tolcapone’s Particle Size on Sustained Release
por: Nardi-Ricart, Anna, et al.
Publicado: (2020)

Cohort study of neurological comorbidities and COVID-19-related case fatality
por: Imbalzano, Gabriele, et al.
Publicado: (2021)

Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection
por: Piazza, Federico, et al.
Publicado: (2021)

Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study
por: Valkovič, Peter, et al.
Publicado: (2022)

Neurological comorbidities and COVID-19-related case fatality: A cohort study
por: Romagnolo, Alberto, et al.
Publicado: (2021)

Efficacy of amantadine in patients hospitalized with COVID-19: Study protocol of a randomized, double-blind, placebo-controlled trial
por: Lopiano, Leonardo, et al.
Publicado: (2021)

Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors
por: Bhakta, Savita G, et al.
Publicado: (2017)

Longitudinal Assessment of Botulinum Toxin Treatment for Lateral Trunk Flexion and Pisa Syndrome in Parkinson’s Disease: Real-life, Long-Term Study
por: Ledda, Claudia, et al.
Publicado: (2023)

Neurological comorbidity and severity of COVID-19
por: Romagnolo, Alberto, et al.
Publicado: (2020)

Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials
por: Merola, Aristide, et al.
Publicado: (2021)

Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis
por: Artusi, Carlo Alberto, et al.
Publicado: (2019)

Predictors and Pathophysiology of Axial Postural Abnormalities in Parkinsonism: A Scoping Review
por: Artusi, Carlo Alberto, et al.
Publicado: (2023)

Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
por: Sant'Anna, Ricardo, et al.
Publicado: (2016)

Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma
por: Maser, Tyler, et al.
Publicado: (2017)

Right inferior frontal cortex activity correlates with tolcapone responsivity in problem and pathological gamblers
por: Kayser, Andrew S., et al.
Publicado: (2016)

Addition of Tolcapone in Intrajejunal Levodopa Infusion Therapy Requires a Pronounced Dose Reduction
por: Schröter, Nils, et al.
Publicado: (2020)

Tolcapone Potently Inhibits Seminal Amyloid Fibrils Formation and Blocks Entry of Ebola Pseudoviruses
por: Qiu, Mengjie, et al.
Publicado: (2020)

Catechol-o-methyltransferase inhibitor tolcapone improves learning and memory in naïve but not in haloperidol challenged rats
por: Mihaylova, Anita, et al.
Publicado: (2019)

Tolcapone in Obsessive Compulsive disorder: A Randomized Double-Blind Placebo-Controlled Crossover Trial
por: Grant, Jon E., et al.
Publicado: (2021)

Author Correction: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
por: Sant’Anna, Ricardo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9k1i7tf6aqm3te2v1q43qca24o